Healthcare / Drug Manufacturers - GeneralBSE
$364.05
+4.20 (+1.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-416.7M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$34.1B
P/E
32.6x
↑EV/EBITDA
20.8x
↑ROE
13.0%
↑Gross Margin
34.1%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+19.5%
FCF CAGR
—
FCF margin
-8.0%
FCF / Net income
-0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.87B · net income $1.02B · FCF $-713.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.87B | $8.87B | $7.83B | $7.06B | $5.20B |
| Net Income | $1.02B | $1.02B | $691.4M | $498.3M | $-70.6M |
| EBITDA | $1.80B | $1.80B | $1.45B | $1.20B | $584.7M |
| EPS | — | — | 8.16 | 5.89 | -0.83 |
| Gross Margin | 34.1% | 34.1% | 33.8% | 29.5% | 24.8% |
| Operating Margin | 14.8% | 14.8% | 13.4% | 12.1% | 4.3% |
| Net Margin | 11.5% | 11.5% | 8.8% | 7.1% | -1.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.49 | 0.52 | 0.55 |
| Current Ratio | 1.81 | 1.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-713.3M | $-713.3M | $-416.7M | $-20.4M | $-74.7M |
| Returns | |||||
| ROE | 13.0% | 13.0% | 10.8% | 9.3% | -1.5% |
| Valuation | |||||
| P/E | 32.62 | 32.62 | 25.72 | 34.91 | — |
| EV/EBITDA | 20.76 | 20.76 | 14.10 | 16.51 | 13.79 |
| P/B | 4.34 | 4.34 | 2.78 | 3.25 | 1.21 |
| Growth & Yield | |||||
| Revenue Growth | 13.3% | 13.3% | 10.8% | 35.9% | — |
| EPS Growth | — | — | 38.5% | 809.6% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+39.4%
Start / end P/E
n/dx → n/dx
EPS bridge
8.16 → n/d
Residual
+39.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.